Amgen Inc. $AMGN Stock: Kelleher Financial Advisors Reduces Holdings

Kelleher Financial Advisors reduced its position in Amgen Inc. (NASDAQ:AMGN) by 48.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,703 shares of the medical research company’s stock after selling 2,553 shares during the quarter. Kelleher Financial Advisors’ holdings in Amgen were worth $1,140,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. BlackRock Inc. grew its position in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. State Street Corp increased its stake in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the period. Bank of America Corp DE purchased a new position in shares of Amgen in the 2nd quarter worth about $1,831,903,000. Finally, Amundi lifted its stake in shares of Amgen by 15.2% in the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $478.48 on Thursday. The company has a market capitalization of $258.68 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 3.38 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $302.13 and a 1-year high of $482.48. The business has a 50-day moving average of $421.56 and a 200-day moving average of $376.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 128.15% and a net margin of 24.14%. The firm had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. During the same quarter in the prior year, the business earned $5.64 EPS. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.1%. Amgen’s dividend payout ratio is 62.65%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported adjusted earnings of $6.45 per share and revenue of $10.37 billion, topping analyst estimates; revenue increased 8.5% year over year. The company also raised its 2026 outlook to $38.9 billion–$39.7 billion in revenue and $18.34–$19.28 in GAAP EPS. Amgen third-quarter financial results
• Positive Sentiment: Growth in medicines including Repatha and IMDELLTRA helped offset pressure elsewhere. Amgen also highlighted pipeline progress, including IMDELLTRA and potential longer-term growth from its obesity candidate MariTide. Amgen raises 2026 outlook
• Positive Sentiment: Several firms raised their targets, including UBS and Scotiabank to $530 and Goldman Sachs to $536, with buy or outperform ratings. These revisions suggest some analysts see further upside after the results. Analyst views and revised targets
• Neutral Sentiment: Analyst opinion remains divided: some target increases still leave estimates below the prevailing share price, and MariTide data is a future catalyst rather than a near-term result. RBC Capital adjusts Amgen target
• Negative Sentiment: Investors remain concerned about steep declines in Prolia and Xgeva as biosimilar competition weighs on sales. That erosion may limit how much growth from newer products translates into future results. Sales and biosimilar concerns

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Wednesday. UBS Group raised their price target on shares of Amgen from $470.00 to $530.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $400.00 price target on shares of Amgen in a research report on Wednesday. Guggenheim decreased their price objective on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a research note on Tuesday, October 13th. Finally, Robert W. Baird increased their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, seventeen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $413.38.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.